| scholarly article | Q13442814 |
| P2093 | author name string | Alisa S Wolberg | |
| James R Byrnes | |||
| P2860 | cites work | Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin | Q77387645 |
| Factor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study | Q77613031 | ||
| Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis | Q77871731 | ||
| Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction | Q78586827 | ||
| Modulation of the risk of coronary sclerosis/myocardial infarction by the interaction between factor XIII subunit A Val34Leu polymorphism and fibrinogen concentration in the high risk Hungarian population | Q79653170 | ||
| Elevated factor XIII level and the risk of myocardial infarction in women | Q79765285 | ||
| Functional analysis of fibrin {gamma}-chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness | Q80160260 | ||
| Down-regulation of activated factor XIII by polymorphonuclear granulocyte proteases within fibrin clot | Q80848283 | ||
| Elevated factor XIII level and the risk of peripheral artery disease | Q81585701 | ||
| Factor XIII-A subunit Val34Leu polymorphism in fatal atherothrombotic ischemic stroke | Q87569644 | ||
| Factor XIII stiffens fibrin clots by causing fiber compaction | Q87628289 | ||
| A novel function of tissue-type transglutaminase: protein disulphide isomerase | Q24530143 | ||
| Amino acid sequence studies on factor XIII and the peptide released during its activation by thrombin | Q28245806 | ||
| Plasma fibronectin promotes thrombus growth and stability in injured arterioles | Q30477630 | ||
| Fibrin fibers have extraordinary extensibility and elasticity | Q30479919 | ||
| Plasma fibronectin supports hemostasis and regulates thrombosis | Q30590791 | ||
| Characterizing the specificity of activated Factor XIII for glutamine-containing substrate peptides | Q33248830 | ||
| Distinct C-terminus of the B subunit of factor XIII in a population-associated major phenotype: the first case of complete allele-specific alternative splicing products in the coagulation and fibrinolytic systems | Q33440810 | ||
| Sensitive and selective detection of free FXIII activation peptide: a potential marker of acute thrombotic events | Q33550678 | ||
| Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction | Q33789267 | ||
| Thiol isomerases in thrombus formation | Q33792729 | ||
| The elasticity of an individual fibrin fiber in a clot | Q33879142 | ||
| Factor XIII activity mediates red blood cell retention in venous thrombi | Q33944224 | ||
| α-α Cross-links increase fibrin fiber elasticity and stiffness | Q34120791 | ||
| Structural origins of fibrin clot rheology | Q34171813 | ||
| Influence of a natural and a synthetic inhibitor of factor XIIIa on fibrin clot rheology. | Q34171820 | ||
| Evidence that αC region is origin of low modulus, high extensibility, and strain stiffening in fibrin fibers | Q34250472 | ||
| Plasma factor XIII binds specifically to fibrinogen molecules containing gamma chains | Q34392346 | ||
| Cystamine preparations exhibit anticoagulant activity | Q34473794 | ||
| Thrombin generation and fibrin clot structure | Q34598931 | ||
| On the Solubility of Fibrin Clots | Q34685095 | ||
| Molecular mechanisms affecting fibrin structure and stability | Q34759786 | ||
| The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis | Q34803276 | ||
| Factor XIII B subunit polymorphisms and the risk of coronary artery disease | Q35016562 | ||
| Functional factor XIII-A is exposed on the stimulated platelet surface | Q35023065 | ||
| Evaluating factor XIII specificity for glutamine-containing substrates using a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay. | Q35153828 | ||
| Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited | Q35690807 | ||
| Ca2+-related regulatory function of fibrinogen | Q35989804 | ||
| Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking | Q36169271 | ||
| Ultrastructure of clots during isometric contraction | Q36206114 | ||
| Factor XIII Val34Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis | Q36494818 | ||
| Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. | Q37623550 | ||
| Factor XIII and venous thromboembolism | Q37860238 | ||
| Factor XIII: a coagulation factor with multiple plasmatic and cellular functions | Q37899674 | ||
| Factor XIII, clot structure, thrombosis. | Q37971200 | ||
| Coagulation factor XIII gene variation, oral contraceptives, and risk of ischemic stroke | Q38459631 | ||
| Protein Disulfide Isomerase in Thrombosis | Q38593275 | ||
| Factor XIII: Structure and Function. | Q38791095 | ||
| Effects of porcine plasmin on the coagulation and fibrinolytic systems in humans | Q39465412 | ||
| Fibrinogen plasma levels modify the association between the factor XIII Val34Leu variant and risk of coronary artery disease: the EPIC-Norfolk prospective population study | Q40301622 | ||
| Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism | Q40379238 | ||
| The Non-catalytic B Subunit of Coagulation Factor XIII Accelerates Fibrin Cross-linking | Q40431605 | ||
| Hypercoagulability and the risk of myocardial infarction and ischemic stroke in young women. | Q40732678 | ||
| The zymogen forms of blood coagulation factor XIII bind specifically to fibrinogen. | Q41621205 | ||
| Coagulation factor XIIIa substrates in human plasma: identification and incorporation into the clot | Q41825512 | ||
| .alpha.-Chain domain of fibrinogen controls generation of fibrinoligase (coagulation factor XIIIa). Calcium ion regulatory aspects | Q72491962 | ||
| Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia | Q72992339 | ||
| Deficiency causing mutations and common polymorphisms in the factor XIII-A gene | Q73139375 | ||
| Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A | Q73139419 | ||
| Factor XIII Val34Leu polymorphism and risk of deep vein thrombosis | Q73387692 | ||
| Interactions of human fibrinogens with factor XIII: roles of calcium and the gamma' peptide | Q73829141 | ||
| Circulating levels of coagulation factor XIII in subjects with type 2 diabetes and in their first-degree relatives | Q73840649 | ||
| The alphaC domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis | Q41938756 | ||
| Impact of fibronectin assembly on platelet thrombus formation in response to type I collagen and von Willebrand factor | Q42008709 | ||
| Coagulation factor XIIIa is inactivated by plasmin. | Q42246877 | ||
| The antifibrinolytic function of factor XIII is exclusively expressed through α₂-antiplasmin cross-linking. | Q42326716 | ||
| Impaired clot retraction in factor XIII A subunit-deficient mice | Q43227254 | ||
| Factor XIIIA-V34L and factor XIIIB-H95R in venous thromboembolism in central Iran: protective and neutral. | Q43636605 | ||
| Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis | Q44163499 | ||
| No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. | Q44342380 | ||
| Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator. | Q44408031 | ||
| Molecular imaging of factor XIIIa activity in thrombosis using a novel, near-infrared fluorescent contrast agent that covalently links to thrombi | Q44947010 | ||
| Coagulation factor XIII Tyr204Phe gene variant and the risk of ischemic stroke. | Q45898080 | ||
| The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. | Q45906428 | ||
| The protective effect of the factor XIII Val34Leu mutation on the risk of deep venous thrombosis is dependent on the fibrinogen level | Q46470732 | ||
| Dicer cleavage by calpain determines platelet microRNA levels and function in diabetes | Q46733192 | ||
| Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction. | Q46752654 | ||
| Coagulation factor XIII serves as protein disulfide isomerase | Q50351432 | ||
| Association of a common polymorphism in the factor XIII gene with venous thrombosis. | Q50538043 | ||
| Platelet factor XIII gene expression and embolic propensity in atrial fibrillation. | Q51165348 | ||
| The activation peptide cleft exposed by thrombin cleavage of FXIII-A(2) contains a recognition site for the fibrinogen α chain. | Q51755292 | ||
| Factor XIII Val34Leu variant protects against coronary artery disease. A meta-analysis. | Q51921214 | ||
| Roles of fibrin α- and γ-chain specific cross-linking by FXIIIa in fibrin structure and function. | Q52840471 | ||
| Interactions between factor XIII and the alphaC region of fibrinogen. | Q52846367 | ||
| A novel polymorphism in the factor XIII B-subunit (His95Arg): relationship to subunit dissociation and venous thrombosis. | Q52857170 | ||
| Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. | Q52860275 | ||
| The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. | Q52863894 | ||
| Association of a common polymorphism in the factor XIII gene with myocardial infarction. | Q52867470 | ||
| Factor XIII activation peptide is released into plasma upon cleavage by thrombin and shows a different structure compared to its bound form. | Q53548493 | ||
| Catalytic life of activated factor XIII in thrombi. Implications for fibrinolytic resistance and thrombus aging. | Q54038073 | ||
| Factor XIII-A dynamics in acute myocardial infarction: a novel prognostic biomarker? | Q54273704 | ||
| Enhanced thrombolysis by a factor XIIIa inhibitor in a rabbit model of femoral artery thrombosis. | Q54321339 | ||
| Resistance of factor XIII to degradation or activation by plasmin. | Q54534019 | ||
| Enzyme-linked immunosorbent assay for the determination of blood coagulation factor XIII A-subunit in plasma and in cell lysates. | Q64882121 | ||
| Factor XIII Deficiency Associated with Klippel-Weber Disease, Platelet Dysfunction and Cryofibrinogenemia | Q67300148 | ||
| Rheological properties of fibrin clots. Effects of fibrinogen concentration, Factor XIII deficiency, and Factor XIII inhibition | Q67316135 | ||
| Interactions of factor XIII with fibrin as substrate and cofactor | Q67731909 | ||
| Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin | Q67801979 | ||
| A photometric assay for blood coagulation factor XIII | Q67943898 | ||
| Crosslinking of rabbit fibrin in vivo | Q68814350 | ||
| Platelet factor XIII is activated by calpain | Q69899268 | ||
| On the retraction of collagen and fibrin induced by normal, defective and modified platelets | Q70096758 | ||
| Role of calcium ion in the generation of factor XIII activity | Q70211618 | ||
| Clot retraction in a factor XIII free system | Q71197597 | ||
| Cross-linking of alpha 2-antiplasmin to fibrin is a key factor in regulating blood clot lysis: species differences | Q71617038 | ||
| Congenital deficiency of factor 13: report of a family from Newfoundland with associated mild deficiency of factor XII | Q71655359 | ||
| Platelet factor XIII becomes active without the release of activation peptide during platelet activation | Q72215963 | ||
| Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIa. Transglutaminase-catalyzed cross-linking to cellular and extracellular structures | Q72221499 | ||
| P433 | issue | 4 | |
| P921 | main subject | thrombosis | Q261327 |
| P304 | page(s) | 445-454 | |
| P577 | publication date | 2016-04-07 | |
| P1433 | published in | Seminars in Thrombosis and Hemostasis | Q15751825 |
| P1476 | title | Newly-Recognized Roles of Factor XIII in Thrombosis | |
| P478 | volume | 42 |
| Q37615581 | Advances of Coagulation Factor XIII |
| Q58554769 | Chronic liver injury drives non-traditional intrahepatic fibrin(ogen) cross-linking via tissue transglutaminase |
| Q92138555 | Coagulation Factor XIII in Cerebral Venous Thrombosis |
| Q58763905 | Cystamine and cysteamine as inhibitors of transglutaminase activity |
| Q47938011 | New findings on venous thrombogenesis |
| Q90444170 | Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a) |
| Q92678389 | Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina |
| Q92433851 | Prediction of Ischemic Events after Percutaneous Coronary Intervention: Thrombelastography Profiles and Factor XIIIa Activity |
| Q48728275 | Screening cleavage of Factor XIII V34X Activation Peptides by thrombin mutants: A strategy for controlling fibrin architecture. |
| Q38801282 | What Is the Biological and Clinical Relevance of Fibrin? |
| Q58122380 | [Variation of expression level and activity of coagulation factor ⅩⅢ in acute myeloid leukemia patients] |
Search more.